Squarepoint
AUTL

Squarepoint’s Autolus Therapeutics AUTL Stock Holding History

Squarepoint’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-91,957
Closed -$150K – 4254
2025
Q3 		$150K Buy
91,957
+78,450
+581% +$153K ﹤0.01% 4025
2025
Q2 		$30.8K Buy
+13,507
New +$22.3K ﹤0.01% 4359
2024
Q3 		– Sell
-20,589
Closed -$71.7K – 4099
2024
Q2 		$71.7K Buy
+20,589
New +$88.8K ﹤0.01% 3860
2023
Q1 		– Sell
-10,407
Closed -$19.8K – 3215
2022
Q4 		$19.8K Buy
+10,407
New +$26.3K ﹤0.01% 3104
2021
Q2 		– Sell
-82,602
Closed -$473K – 3214
2021
Q1 		$473K Buy
+82,602
New +$611K ﹤0.01% 2069
2020
Q3 		– Sell
-30,018
Closed -$481K – 2480
2020
Q2 		$481K Buy
30,018
+14,722
+96% +$163K 0.01% 1341
2020
Q1 		$92K Buy
+15,296
New +$141K ﹤0.01% 1654

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Squarepoint's AUTL Position: Q4 2025 in Review

Squarepoint sold out of Autolus Therapeutics (AUTL) in Q4 2025, closing a stake of 91,957 shares — an estimated $150K sold.

Squarepoint first reported a position in AUTL in Q1 2020 and held it in 7 quarters. The position peaked at $481K in Q2 2020. 89 funds tracked by Wall St. Rank hold AUTL as of Q4 2025.

  • Squarepoint reported no remaining Autolus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 91,957 Autolus Therapeutics shares in Q4 2025, an estimated $150K.
  • Squarepoint first reported a position in Autolus Therapeutics in Q1 2020 and held it in 7 quarters.
  • Squarepoint's Autolus Therapeutics position peaked at $481K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.